Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022:33:100661.
doi: 10.1016/j.ctarc.2022.100661. Epub 2022 Nov 20.

Non-urothelial and urothelial variants of bladder cancer

Affiliations
Free article
Review

Non-urothelial and urothelial variants of bladder cancer

Eun-Mi Yu et al. Cancer Treat Res Commun. 2022.
Free article

Abstract

Non-urothelial bladder cancers make up a rare minority of all genitourinary (GU) tract histologic cancers since urothelial cancer (UC) makes up the most common histologic subtype. Bladder cancer variant histology (BCVH) or urothelial variants also occur rarely though distinction is important given aggressive presentation and natural history. While methods for diagnosis and treatment of typical urothelial cancers (UC) are well-established, there are no clear guidelines with regard to the diagnosis of non-urothelial bladder cancers, which often results in misdiagnosis and treatment delay. This review will focus on the clinicopathologic characteristics of the most common non-urothelial bladder cancers, to be distinguished from bladder cancer variant histology containing a UC component. The role of genomics in non-urothelial bladder cancers is evolving and the use of biomarkers to guide the diagnosis and treatment of these tumors remains a key area of unmet need. Treatment of these cancers will be discussed in a companion review.

Keywords: Adenocarcinoma; Bladder sarcomas; Carcinosarcomas; Non-urothelial bladder cancers; Squamous cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest JAC serves on the Speakers’ Bureau of BMS, Astellas/SeaGen and Pfizer/EMD Serono. JAC serves on the Advisory Board of Exelixis, Immunomedics, AVEO Pharmaceuticals, Janssen, Pfizer/Myovant, Merck, AZD. The rest of the authors have no conflict to declare.

MeSH terms

LinkOut - more resources